CING
Cingulate Inc.
1W: -15.1%
1M: +22.0%
3M: +93.2%
YTD: +68.5%
1Y: +94.2%
3Y: -97.0%
$7.38
-0.13 (-1.73%)
After Hours: $7.28 (-0.10, -1.42%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$41.4M
52W Range3.2-11.89
Volume1,181,668
Avg Volume411,798
Beta-0.77
Dividend—
Analyst Ratings
Company Info
CEOShane J. Schaffer
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date2021-12-08
Websitecingulate.com
1901 West 47th Place
Kansas City, KS 66205
US
Kansas City, KS 66205
US
913 942 2300
About Cingulate Inc.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Latest News
What's Going On With Cingulate Stock Today?
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Silva Raul R. | A-Award | 4,526 | — | 2026-03-09 |
| Silva Raul R. | F-InKind | 1,828 | — | 2026-03-09 |
| Schaffer Shane J. | A-Award | 6,862 | — | 2026-03-09 |
| Schaffer Shane J. | F-InKind | 2,959 | — | 2026-03-09 |
| Callahan Jennifer L. | A-Award | 15,329 | — | 2026-03-09 |